Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 138

1.

'New/Designer Benzodiazepines': an analysis of the literature and psychonauts' trip reports.

Orsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, De Berardis D, Papanti D, Schifano F.

Curr Neuropharmacol. 2020 Jan 10. doi: 10.2174/1570159X18666200110121333. [Epub ahead of print]

PMID:
31933443
2.

The Bridge Between Classical and "Synthetic"/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective.

Orsolini L, Chiappini S, Papanti D, De Berardis D, Corkery JM, Schifano F.

Front Psychiatry. 2019 Nov 20;10:851. doi: 10.3389/fpsyt.2019.00851. eCollection 2019. Review.

3.

How deaths can help clinicians and policy-makers understand the risks of novel psychoactive substances.

Corkery JM, Schifano F, Martinotti G.

Br J Clin Pharmacol. 2019 Nov 26. doi: 10.1111/bcp.14183. [Epub ahead of print] Review.

PMID:
31770457
4.

The clinical challenges of synthetic cathinones.

Schifano F, Napoletano F, Arillotta D, Zangani C, Gilgar L, Guirguis A, Corkery JM, Vento A.

Br J Clin Pharmacol. 2019 Nov 1. doi: 10.1111/bcp.14132. [Epub ahead of print]

PMID:
31674690
5.

Quetiapine Abuse Fourteen Years Later: Where Are We Now? A Systematic Review.

Vento AE, Kotzalidis GD, Cacciotti M, Papanti GD, Orsolini L, Rapinesi C, Savoja V, Calabrò G, Del Casale A, Piacentino D, Caloro M, Girardi P, Schifano F.

Subst Use Misuse. 2020;55(2):304-313. doi: 10.1080/10826084.2019.1668013. Epub 2019 Oct 1.

PMID:
31573374
6.

The use of new psychoactive substances (NPS) in young people and their role in mental health care: a systematic review.

Orsolini L, Chiappini S, Corkery JM, Guirguis A, Papanti D, Schifano F.

Expert Rev Neurother. 2019 Dec;19(12):1253-1264. doi: 10.1080/14737175.2019.1666712. Epub 2019 Sep 24.

PMID:
31503507
7.

Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances.

Deligianni E, Daniel OJ, Corkery JM, Schifano F, Lione LA.

Br J Clin Pharmacol. 2019 Sep 8. doi: 10.1111/bcp.14123. [Epub ahead of print]

PMID:
31495968
8.

Characteristics of deaths associated with kratom use.

Corkery JM, Streete P, Claridge H, Goodair C, Papanti D, Orsolini L, Schifano F, Sikka K, Körber S, Hendricks A.

J Psychopharmacol. 2019 Sep;33(9):1102-1123. doi: 10.1177/0269881119862530. Epub 2019 Aug 20.

PMID:
31429622
9.

Cannabidiol (CBD) use in psychiatric disorders: A systematic review.

Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F.

Neurotoxicology. 2019 Sep;74:282-298. doi: 10.1016/j.neuro.2019.08.002. Epub 2019 Aug 11. Review.

PMID:
31412258
10.

Pregabalin: A range of misuse-related unanswered questions.

Schifano F, Chiappini S.

CNS Neurosci Ther. 2019 May;25(5):659-660. doi: 10.1111/cns.13115. Epub 2019 Mar 4. No abstract available.

11.

Assessing the 2004-2018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting Systems.

Schifano F, Chiappini S, Corkery JM, Guirguis A.

Front Pharmacol. 2019 Feb 1;10:46. doi: 10.3389/fphar.2019.00046. eCollection 2019.

12.

Dorsolateral Prefrontal Cortex Impairment in Methoxetamine-Induced Psychosis: An 18F-FDG PET/CT Case Study.

Moccia L, Tofani A, Mazza M, Covino M, Martinotti G, Schifano F, Janiri L, Di Nicola M.

J Psychoactive Drugs. 2019 Jul-Aug;51(3):254-259. doi: 10.1080/02791072.2019.1578444. Epub 2019 Feb 9.

PMID:
30741111
13.

An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions.

Schifano F, Chiappini S, Corkery JM, Guirguis A.

Int J Neuropsychopharmacol. 2019 Apr 1;22(4):270-277. doi: 10.1093/ijnp/pyz007.

14.

Recent Changes in Drug Abuse Scenarios: The New/Novel Psychoactive Substances (NPS) Phenomenon.

Schifano F.

Brain Sci. 2018 Dec 13;8(12). pii: E221. doi: 10.3390/brainsci8120221.

15.

Patterns of Management of Patients With Dual Disorder (Psychosis) in Italy: A Survey of Psychiatrists and Other Physicians Focusing on Clinical Practice.

Clerici M, de Bartolomeis A, De Filippis S, Ducci G, Maremmani I, Martinotti G, Schifano F.

Front Psychiatry. 2018 Nov 13;9:575. doi: 10.3389/fpsyt.2018.00575. eCollection 2018.

16.

Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports.

Schifano F, Chiappini S.

PLoS One. 2018 Oct 4;13(10):e0204443. doi: 10.1371/journal.pone.0204443. eCollection 2018.

17.

Synthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues.

Bonaccorso S, Metastasio A, Ricciardi A, Stewart N, Jamal L, Rujully NU, Theleritis C, Ferracuti S, Ducci G, Schifano F.

Brain Sci. 2018 Jul 14;8(7). pii: E133. doi: 10.3390/brainsci8070133.

18.

Joint versus separate inpatient rehabilitation treatment for patients with alcohol use disorder or drug use disorder: an observational study.

Bender S, Specka M, Buchholz A, Hölscher S, Rist F, Heinz TW, Schifano F, Scherbaum N.

Subst Abuse Rehabil. 2018 Jun 25;9:23-29. doi: 10.2147/SAR.S136523. eCollection 2018.

19.

Psychedelic Fauna for Psychonaut Hunters: A Mini-Review.

Orsolini L, Ciccarese M, Papanti D, De Berardis D, Guirguis A, Corkery JM, Schifano F.

Front Psychiatry. 2018 May 22;9:153. doi: 10.3389/fpsyt.2018.00153. eCollection 2018. Review.

20.

"Marvin, the Paranoid Android": The Case of an Alpha-PVP User in the Expanding Galaxy of NPS.

Pierluigi S, Laura B, Attilio N, Gurjeet K B, Gloria P, Davide M, Borgherini G, Giovanni M, Fabrizio S, Perini G, Ornella C.

J Psychoactive Drugs. 2018 Sep-Oct;50(4):306-313. doi: 10.1080/02791072.2018.1447172. Epub 2018 May 16.

PMID:
29768112

Supplemental Content

Loading ...
Support Center